Novartis reports sharply higher half-year profits
AFP/The Local · 17 Jul 2014, 09:22
Published: 17 Jul 2014 09:22 GMT+02:00
- Japan charges Novartis unit over falsified data (01 Jul 14)
- Japan nabs ex-Novartis worker for 'false data' (11 Jun 14)
- Unit sale drives rise in Novartis Q1 net profits (24 Apr 14)
Driven by strong sales in emerging markets such as China and Russia, net profits for the first six months rose to $5.56 billion, compared to $4.97 billion for the same period in 2013, the group said on Thursday.
Group turnover also grew, but at a slower rate, rising two percent to $28.66 billion, according to the earnings statement.
Novartis boss Joseph Jimenez hailed what he called his group's "solid financial performance".
The Basel-based pharma titan said it was keeping its full-year forecast of a growth in turnover of "low to mid-single digits".
In the second quarter, profits rose by three percent to reach $2.58 billion, Novartis said.
Novartis has seen radical changes in the past few months, announcing in April a string of multi-billion-dollar deals with rival GlaxoSmithKline in what Jimenez described as a "transformational moment" for the Swiss group.
The deals will see Novartis sharpen its focus on the high-grossing cancer sector and GSK seeking to boost its share in the vaccine market.